Effects of erythropoietin after an acute myocardial infarction: Rationale and study design of a prospective, randomized, clinical trial (HEBE III) - 09/08/11
, Wiek H. van Gilst, PhD b, Stefan D. Anker, MD, PhD c, Riemer H. Slart, MD, PhD d, Rene A. Tio, MD, PhD a, Felix Zijlstra, MD, PhD a, Dirk J. van Veldhuisen, MD, PhD aon behalf of the HEBE III investigators
Résumé |
Background |
Preclinical studies have consistently shown that erythropoietin (EPO), administered after an acute myocardial infarction (AMI), reduces infarct size and improves left ventricular function. Furthermore, EPO promotes endothelial progenitor cell growth, which increases angiogenesis. A recent pilot study in patients with AMI suggested that a single bolus of EPO was safe and well tolerated.
Methods |
The HEBE III is a multicenter, prospective, randomized, open-label trial with blinded evaluation of the primary end point. The primary objective is to study the effect on left ventricular ejection fraction (LVEF) of a single bolus of EPO, administered directly after a primary percutaneous coronary intervention (PCI) for a first AMI. A total of 466 patients with thrombolysis in myocardial infarction 0/1 flow before the PCI procedure and 2/3 flow after a successful PCI are randomly assigned to either receive standard medical care or a single bolus with 60,000 IU of EPO on top of standard medical care within 3 hours of the PCI procedure. Primary end point of the study is LVEF after 6 weeks, assessed by planar radionuclide ventriculography.
Implications |
If an improvement of LVEF with a single bolus of EPO is demonstrated, this simple approach might further improve clinical outcome of patients with AMI.
Le texte complet de cet article est disponible en PDF.Plan
| Doctor DJ van Veldhuisen and AA Voors are clinical established investigators of the Netherlands Heart Foundation. This study was supported by grants from the Interuniversity Cardiology Institute of the Netherlands and the Netherlands Heart Foundation (D97-017 and 2006T37), and a research grant was received from Ortho Biotech, a division of Janssen-Cilag BV, the Netherlands. |
Vol 155 - N° 5
P. 817-822 - mai 2008 Retour au numéro
Article précédent
- Routine hematologic clinical tests as prognostic markers in patients with acute coronary syndromes
- Samuel J. Turner, Terry R. Ketch, Sanjay K. Gandhi, David C. Sane
- The genetic response to short-term interventions affecting cardiovascular function: Rationale and design of the Heredity and Phenotype Intervention (HAPI) Heart Study
- Braxton D. Mitchell, Patrick F. McArdle, Haiqing Shen, Evadnie Rampersaud, Toni I. Pollin, Lawrence F. Bielak, Cashell Jaquish, Julie A. Douglas, Marie-Hélène Roy-Gagnon, Paul Sack, Rosalie Naglieri, Scott Hines, Richard B. Horenstein, Yen-Pei C. Chang, Wendy Post, Kathleen A. Ryan, Nga Hong Brereton, Ruth E. Pakyz, John Sorkin, Coleen M. Damcott, Jeffrey R. O'Connell, Charles Mangano, Mary Corretti, Robert Vogel, William Herzog, Matthew R. Weir, Patricia A. Peyser, Alan R. Shuldiner
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?